Could a brain cancer drug target tumor activity? early trial launches

NCT ID NCT06552260

Recruiting now Disease control Sponsor: Ugonma Chukwueke Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests the drug troriluzole in 27 adults with recurrent IDH wild-type glioblastoma, an aggressive brain cancer. Participants take the drug before surgery, and researchers measure brain activity and glutamate levels in the removed tumor tissue. The goal is to see if troriluzole affects tumor-related brain signals, not yet to prove it works as a treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Troriluzole (a prodrug of riluzole, taken as a capsule)
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a difficult-to-treat brain cancer.
What could go wrong: This is a very early (Phase 1) trial with only 27 people, so it is too soon to know if troriluzole is safe or effective. The main goal is to measure brain activity and drug levels, not to prove clinical benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN TUMOR GLIOBLASTOMA RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital Cancer Center
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.